Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PD-L1 overexpression
i
Other names:
PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
29126
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Related tests:
PD-L1 IHC 22C3 pharmDx (55)
VENTANA PD-L1 (SP263) Assay (31)
PD-L1 IHC 22C3 pharmDx (55)
VENTANA PD-L1 (SP263) Assay (31)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
cemiplimab-rwlc
Sensitive: A1 - Approval
cemiplimab-rwlc
Sensitive
:
A1
cemiplimab-rwlc
Sensitive: A1 - Approval
cemiplimab-rwlc
Sensitive
:
A1
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
PD-L1 overexpression
Urothelial Cancer
PD-L1 overexpression
Urothelial Cancer
tislelizumab-jsgr
Sensitive: A1 - Approval
tislelizumab-jsgr
Sensitive
:
A1
tislelizumab-jsgr
Sensitive: A1 - Approval
tislelizumab-jsgr
Sensitive
:
A1
PD-L1 overexpression
Gastroesophageal Junction Adenocarcinoma
PD-L1 overexpression
Gastroesophageal Junction Adenocarcinoma
tislelizumab-jsgr
Sensitive: A1 - Approval
tislelizumab-jsgr
Sensitive
:
A1
tislelizumab-jsgr
Sensitive: A1 - Approval
tislelizumab-jsgr
Sensitive
:
A1
PD-L1 overexpression
Gastric Cancer
PD-L1 overexpression
Gastric Cancer
tislelizumab-jsgr
Sensitive: A1 - Approval
tislelizumab-jsgr
Sensitive
:
A1
tislelizumab-jsgr
Sensitive: A1 - Approval
tislelizumab-jsgr
Sensitive
:
A1
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
durvalumab
Sensitive: A2 - Guideline
durvalumab
Sensitive
:
A2
durvalumab
Sensitive: A2 - Guideline
durvalumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
bevacizumab + atezolizumab
Sensitive
:
A2
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
bevacizumab + atezolizumab
Sensitive
:
A2
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
cemiplimab-rwlc
Sensitive: A2 - Guideline
cemiplimab-rwlc
Sensitive
:
A2
cemiplimab-rwlc
Sensitive: A2 - Guideline
cemiplimab-rwlc
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
durvalumab + tremelimumab
Sensitive: A2 - Guideline
durvalumab + tremelimumab
Sensitive
:
A2
durvalumab + tremelimumab
Sensitive: A2 - Guideline
durvalumab + tremelimumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
durvalumab + tremelimumab
Sensitive: A2 - Guideline
durvalumab + tremelimumab
Sensitive
:
A2
durvalumab + tremelimumab
Sensitive: A2 - Guideline
durvalumab + tremelimumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
cemiplimab-rwlc
Sensitive: A2 - Guideline
cemiplimab-rwlc
Sensitive
:
A2
cemiplimab-rwlc
Sensitive: A2 - Guideline
cemiplimab-rwlc
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
atezolizumab + RG6058
Sensitive: B - Late Trials
atezolizumab + RG6058
Sensitive
:
B
atezolizumab + RG6058
Sensitive: B - Late Trials
atezolizumab + RG6058
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
carboplatin + albumin-bound paclitaxel
Sensitive: B - Late Trials
carboplatin + albumin-bound paclitaxel
Sensitive
:
B
carboplatin + albumin-bound paclitaxel
Sensitive: B - Late Trials
carboplatin + albumin-bound paclitaxel
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
carboplatin + gemcitabine
Sensitive: B - Late Trials
carboplatin + gemcitabine
Sensitive
:
B
carboplatin + gemcitabine
Sensitive: B - Late Trials
carboplatin + gemcitabine
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
cisplatin + albumin-bound paclitaxel
Sensitive: B - Late Trials
cisplatin + albumin-bound paclitaxel
Sensitive
:
B
cisplatin + albumin-bound paclitaxel
Sensitive: B - Late Trials
cisplatin + albumin-bound paclitaxel
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
Sensitive: B - Late Trials
Sensitive
:
B
Sensitive: B - Late Trials
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
carboplatin + pemetrexed
Sensitive: B - Late Trials
carboplatin + pemetrexed
Sensitive
:
B
carboplatin + pemetrexed
Sensitive: B - Late Trials
carboplatin + pemetrexed
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
cisplatin + pemetrexed
Sensitive: B - Late Trials
cisplatin + pemetrexed
Sensitive
:
B
cisplatin + pemetrexed
Sensitive: B - Late Trials
cisplatin + pemetrexed
Sensitive
:
B
PD-L1 overexpression
Gastroesophageal Cancer
PD-L1 overexpression
Gastroesophageal Cancer
PD1 inhibitor
Sensitive: B - Late Trials
PD1 inhibitor
Sensitive
:
B
PD1 inhibitor
Sensitive: B - Late Trials
PD1 inhibitor
Sensitive
:
B
PD-L1 overexpression
Gastroesophageal Cancer
PD-L1 overexpression
Gastroesophageal Cancer
PD-L1 inhibitor
Sensitive: B - Late Trials
PD-L1 inhibitor
Sensitive
:
B
PD-L1 inhibitor
Sensitive: B - Late Trials
PD-L1 inhibitor
Sensitive
:
B
PD-L1 overexpression
Triple Negative Breast Cancer
PD-L1 overexpression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: B - Late Trials
pembrolizumab
Sensitive
:
B
pembrolizumab
Sensitive: B - Late Trials
pembrolizumab
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
tislelizumab-jsgr
Sensitive: B - Late Trials
tislelizumab-jsgr
Sensitive
:
B
tislelizumab-jsgr
Sensitive: B - Late Trials
tislelizumab-jsgr
Sensitive
:
B
PD-L1 overexpression
Urothelial Cancer
PD-L1 overexpression
Urothelial Cancer
durvalumab
Sensitive: B - Late Trials
durvalumab
Sensitive
:
B
durvalumab
Sensitive: B - Late Trials
durvalumab
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
nivolumab
Sensitive: B - Late Trials
nivolumab
Sensitive
:
B
nivolumab
Sensitive: B - Late Trials
nivolumab
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
M7824
Sensitive: B - Late Trials
M7824
Sensitive
:
B
M7824
Sensitive: B - Late Trials
M7824
Sensitive
:
B
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login